Bioventus (NYSE:BVS) Given New $16.00 Price Target at Craig Hallum

Bioventus (NYSE:BVS) had its price objective upped by stock analysts at Craig Hallum from $15.00 to $16.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Craig Hallum’s price objective suggests a potential upside of 91.16% from the company’s current price.

Separately, Barrington Research assumed coverage on shares of Bioventus in a research report on Monday, February 9th. They set an “outperform” rating and a $13.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $14.00.

Bioventus Stock Down 8.0%

BVS traded down $0.73 during trading hours on Friday, hitting $8.37. 180,112 shares of the company’s stock were exchanged, compared to its average volume of 272,959. Bioventus has a 12-month low of $5.81 and a 12-month high of $11.25. The firm has a 50 day moving average of $8.10 and a 200 day moving average of $7.49. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The firm has a market cap of $692.73 million, a P/E ratio of -13.72 and a beta of 0.78.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after acquiring an additional 1,538 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Bioventus by 19.1% during the first quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock valued at $1,486,000 after purchasing an additional 26,103 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Bioventus during the 2nd quarter worth about $179,000. Fox Run Management L.L.C. acquired a new stake in Bioventus during the 2nd quarter worth about $72,000. Finally, Los Angeles Capital Management LLC increased its holdings in shares of Bioventus by 23.2% in the 2nd quarter. Los Angeles Capital Management LLC now owns 121,835 shares of the company’s stock valued at $807,000 after purchasing an additional 22,915 shares during the period. 62.94% of the stock is currently owned by institutional investors and hedge funds.

About Bioventus

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.